Exosome-derived miR-210 involved in resistance to osimertinib and epithelial-mesenchymal transition in EGFR mutant non-small cell lung cancer cells - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33939301/
Background: Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) approved for the treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC). However, the mechanisms of acquired...
-
Naveed Saleh, MD, MS – Skipta Team5yrKey Points • In the current preclinical study, researchers employed established osimertinib‐resistant HCC827 (HCC827‐OR) and PC‐9 (PC‐9‐OR) cells to assess the profiles of exosomal miRNA linked to resistance to osimertinib in Show More
Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33952592/
The growing numbers of therapeutic biomarkers in NSCLC requires judicious triage of limited-volume tissue from small specimens. Our study showed that thoracic small tissue specimens can be used successfully to...
Prognostic Significance of EGFR Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care Alone - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33952497/
1 Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan; [email protected]. 2 Department of Molecular and Internal Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan. 3...
Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33940786/
Our study reveals that the T790M mutation in EGFR-KDD confers resistance to 1st and 2nd generation EGFR TKIs, but is sensitive to 3rd generation EGFR TKIs. In addition, we identified...
Key Points
• In the current study, the authors analyzed characteristics of patients treated with tyrosine kinase inhibitors (TKIs) with either de novo or secondary metastatic EGFR NSCLC.
• According to the authors, “A first important finding is that the setting of stage IV disease, de novo vs. secondary, itself is not associated with...
De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33898315/
Despite the survival advantage reported in the pre-TKI era for relapsed NSCLC, molecular features and outcome of TKI-treated metastatic EGFR + tumors are currently independent of preceding nonmetastatic disease. This...